expression and participate in almost all biological processes, such as cell proliferation, differentiation,
and apoptosis. Besides being important cellular regulators miRNAs have become useful biomarkers in
diagnosis of numerous diseases . The altered expression of individual miRNAs has been
demonstrated in numerous cancers . However, detecting and quantifying miRNAs accurately can be
challenging, often relying on PCR amplification, which doesn’t allow direct analysis. Here, we are
introducing a novel method for direct and PCR-free detection of microRNA-122 (miR-122) , a
promising biomarker for liver function and liver disease diagnosis.
Methods: The current study describes a comparative performance assessment between Luminex
MAGPIX® and FLEXMAP 3D® platforms to detect miR-122 in human serum. Experiments were
performed under comparable conditions using DESTINA’s ChemiRNATM technology on the two Luminex
platforms. Assay procedure: a) Modified capture probes (complementary to target miR-122) are
conjugated onto Luminex microspheres; b) Microspheres are incubated with serum sample; c)
Modified capture probes hybridize with miR-122, forming a chemical pocket; d) A modified base binds
in the pocket which can be detected after the application of streptavidin-phycoerythrin. This
comparative study has included six serum samples of liver-diseased individuals, as well as four control
samples of symptom-free individuals, measured in triplicates and quantified using a 9-point standard
Results: We observed FLEXMAP to be more sensitive in detecting miRNA-122 and resulting in higher
signal intensities than MAGPIX. This result was not unexpected as MAGPIX measures fluorescence with
CCD cameras after LED illumination of a single layer of microspheres, whereas FLEXMAP uses a flow
cytometer-based technology in combination with lasers.
Conclusions: ChemiRNA™ Technology applied to Luminex microspheres enables direct quantification
of miR-122 and can be used in combination with both platforms (MAGPIX and FLEXMAP) depending
on given sensitivity requirements.
 Condrat et al. miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis
and Prognosis Cells. 2020, 9(2): 276.
 Marín-Romero et al. Amplification-free profiling of microRNA-122 biomarker in DILI patient
serums, using the luminex MAGPIX system. Talanta. 2020, 219:121265.
|Publikationsstatus||Veröffentlicht - 2023|
|Veranstaltung||CCC-Trio 2023 Symposium: Cutting-Edge Krebstherapie und -Forschung - Vienna, Österreich|
Dauer: 27 Apr. 2023 → 28 Apr. 2023
|Konferenz||CCC-Trio 2023 Symposium|
|Zeitraum||27/04/23 → 28/04/23|
- Molecular Diagnostics